The goal of this PPG, Gene Therapy for Pulmonary and Hematologic Disorders, is to facilitate translation of basic knowledge of gene delivery to safe and rigorous human clinical trials. The long-range goal is to provide novel therapeutic modalities for treating monogenetic diseases such as Hemophilia and Cystic Fibrosis. The major objectives in the UNC PPG are: (1) the development of highly efficient and high titer viral vectors, optimum expression, and safe persisting delivery systems, and (2) development of novel animal models for better defining rate limiting steps involved in target cell transduction, analysis of long term high level vector gene expression, and expression of normal and mutant human genes (e.g. FIX, CFTR). Four basic science projects and four cores are proposed. The basic research projects are proposed to focus on understanding rate-limiting steps in effective gene transfer. Projects 1 and 2 focus on AAV (Samulski) and Lentivirus (Olsen and Kafri), respectively. These projects are aimed at understanding and overcoming inefficient gene delivery related to virus entry and persistent transgene expression. The goal of the proposed studies is to generate new knowledge about the safety and biological efficacy of gene delivery, which will provide information important to the design of future clinical trials. Projects 3 and 4 involve animal models for airway (Boucher) and hemophilia (Stafford) disorders, respectively. These studies aim to define the host-associated rate limiting step(s) for understanding of the cell biology of the target tissue for efficient in vivo gene delivery and translating improvements in vector development. Specifically, goals include increasing access to airway epithelia (Project 3), development of novel models (e.g. a humanized hemophilia mouse, Project 4). This work will be supported by four cores, Administrative (Core A), Vector (Core B), Animal (Core C), and Morphology (Core D). The PPG is a highly interactive program comprised of clinical investigators and expert basic laboratories designed to optimize vectors and to test their interactions with target cells in vitro and in vivo. The ultimate goal of the UNC PPG is to achieve safe, effective, gene delivery in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL066973-04
Application #
6788818
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Banks-Schlegel, Susan P
Project Start
2001-09-30
Project End
2006-07-31
Budget Start
2004-08-01
Budget End
2005-07-31
Support Year
4
Fiscal Year
2004
Total Cost
$1,852,206
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Monahan, Paul E; Sun, Junjiang; Gui, Tong et al. (2015) Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 26:69-81
Monahan, P E (2015) Gene therapy in an era of emerging treatment options for hemophilia B. J Thromb Haemost 13 Suppl 1:S151-60
Piacentino 3rd, Valentino; Milano, Carmelo A; Bolanos, Michael et al. (2012) X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. Hum Gene Ther 23:635-46
Kantor, Boris; Bayer, Matthew; Ma, Hong et al. (2011) Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Mol Ther 19:547-56
Cockrell, Adam S; van Praag, Henriette; Santistevan, Nicholas et al. (2011) The HIV-1 Rev/RRE system is required for HIV-1 5' UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles. Retrovirology 8:51
Monahan, Paul E; Lothrop, Clinton D; Sun, Junjiang et al. (2010) Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther 18:1907-16
Li, C; Hirsch, M; Carter, P et al. (2009) A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther 16:43-51
Gui, T; Reheman, A; Ni, H et al. (2009) Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 7:1843-51
Li, Chengwen; Goudy, Kevin; Hirsch, Matt et al. (2009) Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A 106:10770-4
Kantor, Boris; Ma, Hong; Webster-Cyriaque, Jennifer et al. (2009) Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci U S A 106:18786-91

Showing the most recent 10 out of 38 publications